Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Newmarket Corp (NEU)

Newmarket Corp (NEU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,037,232
  • Shares Outstanding, K 9,589
  • Annual Sales, $ 2,698 M
  • Annual Income, $ 388,860 K
  • 60-Month Beta 0.45
  • Price/Sales 2.22
  • Price/Cash Flow 12.94
  • Price/Book 5.61
Trade NEU with:

Options Overview Details

View History
  • Implied Volatility 17.32% ( +0.17%)
  • Historical Volatility 14.28%
  • IV Percentile 39%
  • IV Rank 33.49%
  • IV High 26.07% on 10/19/23
  • IV Low 12.91% on 12/05/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 56
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 432
  • Open Int (30-Day) 421

Price Performance

See More
Period Period Low Period High Performance
1-Month
602.99 +5.24%
on 03/13/24
650.00 -2.37%
on 03/04/24
+0.99 (+0.16%)
since 02/28/24
3-Month
539.83 +17.56%
on 01/02/24
650.00 -2.37%
on 03/04/24
+84.82 (+15.43%)
since 12/28/23
52-Week
359.14 +76.71%
on 03/30/23
650.00 -2.37%
on 03/04/24
+275.09 (+76.51%)
since 03/28/23

Most Recent Stories

More News
Did You Know These 3 Dividend Growth Stocks Are up Over 80%?

These are three dividend growth stocks with more than 80% returns YoY.

LII : 488.76 (+0.43%)
NEU : 634.62 (+0.80%)
WSM : 317.53 (+1.12%)
NewMarket: Q4 Earnings Snapshot

NewMarket: Q4 Earnings Snapshot

NEU : 634.62 (+0.80%)
NewMarket: Q3 Earnings Snapshot

NewMarket: Q3 Earnings Snapshot

NEU : 634.62 (+0.80%)
Chart of the Day: NewMarket - ICE Performance Enhancement Products

The Chart of the Day belongs to internal combustion engine performance enhancement products company NewMarket (NEU) . I found the stock by using Barchart's powerful screening functions to find stocks...

NEU : 634.62 (+0.80%)
NewMarket: Q2 Earnings Snapshot

NewMarket: Q2 Earnings Snapshot

NEU : 634.62 (+0.80%)
NewMarket Corporation Increases Quarterly Dividend

The Board of Directors of NewMarket Corporation (NYSE: NEU) declared a quarterly dividend in the amount of $2.25 per share on the common stock of the Corporation, an increase of $0.15 as compared to the...

NEU : 634.62 (+0.80%)
NewMarket: Q1 Earnings Snapshot

NewMarket: Q1 Earnings Snapshot

NEU : 634.62 (+0.80%)
NewMarket Corporation Reports First Quarter 2023 Results

NewMarket Corporation (NYSE:NEU) Chairman and Chief Executive Officer, Thomas E. Gottwald, released the following earnings report of the Company’s operations for the first quarter of 2023.

NEU : 634.62 (+0.80%)
NewMarket Corporation Schedules Conference Call and Webcast to Review First Quarter 2023 Financial Results

NewMarket Corporation (NYSE: NEU) announced today it expects to release first quarter 2023 earnings at the close of business on Wednesday, April 26, 2023. The earnings announcement will also be available...

NEU : 634.62 (+0.80%)
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUEâ„¢ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE â„¢ (trofinetide) for the treatment of Rett syndrome in adult and pediatric...

ACAD : 18.49 (+1.59%)
NEU : 634.62 (+0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NewMarket Corporation through its subsidiaries, Afton Chemical Corporation and Ethyl Corporation, develops, manufactures, blends, and delivers chemical additives that enhance the performance of petroleum products. From custom-formulated chemical blends to market-general additive components, the NewMarket...

See More

Key Turning Points

3rd Resistance Point 643.96
2nd Resistance Point 641.09
1st Resistance Point 637.85
Last Price 634.62
1st Support Level 631.74
2nd Support Level 628.87
3rd Support Level 625.63

See More

52-Week High 650.00
Last Price 634.62
Fibonacci 61.8% 538.89
Fibonacci 50% 504.57
Fibonacci 38.2% 470.25
52-Week Low 359.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar